目的 探討尤瑞克林聯(lián)合依達(dá)拉奉對(duì)急性腦梗死患者血清同型半胱氨酸（Hcy）、血清超敏C-反應(yīng)蛋白（hs-CRP）和D-二聚體水平的影響。方法 將河南大學(xué)附屬南陽(yáng)南石醫(yī)院自2015年1月-2017年10月收治的急性腦梗死患者160例作為研究對(duì)象，隨機(jī)分為兩組，觀察組86例給予尤瑞克林聯(lián)合依達(dá)拉奉進(jìn)行治療，對(duì)照組74例單純給予依達(dá)拉奉進(jìn)行治療，兩組均治療2周。對(duì)比觀察兩組患者的治療效果和血清Hcy、hs-CRP和D-二聚體水平變化情況。結(jié)果 觀察組患者治療后臨床總有效率為91.86%，顯著高于對(duì)照組的79.73%，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后兩組患者Hcy、hs-CRP和D-二聚體水平及NIHSS評(píng)分均顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且觀察組以上指標(biāo)顯著低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 對(duì)急性腦梗死患者在常規(guī)治療的基礎(chǔ)上使用尤瑞克林聯(lián)合依達(dá)拉奉治療，可有效改善患者臨床效果、神經(jīng)功能恢復(fù)，降低血清炎癥介質(zhì)的水平，達(dá)到改善預(yù)后的目的，可推廣使用。

Objective To investigate the effect of uricorlin combined with edaravone on the levels of serum Hcy, hs-CRP and D-dimer in patients with acute cerebral infarction. Methods 160 patients with acute cerebral infarction treated in our hospital from January 2015 to October 2017 were randomly divided into two groups. The study group was treated with urelixin and edaravone in 86 cases. In the control group, 74 cases were treated with edaravone alone. The treatment effects and changes of serum inflammatory factors in the two groups were observed and compared.Results The total effective rate was 91.86% in the study group and 79.73% in the control group. The difference between the two groups was statistically significant (P<0.05). The scores of hs-CRP, D-dimer, and NIHSS scores were significantly lower, and the reduction level in the study group was significantly better than that in the control group. The difference between the groups was statistically significant (P<0.05).Conclusion s The use of urelixin in combination with edaravone in the treatment of acute cerebral infarction patients can effectively improve the clinical efficacy and neurological function recovery, reduce the level of serum inflammatory mediators, can improve the prognosis and can be promoted.

國(guó)家自然青年基金項(xiàng)目（81500323）